Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II weekly irinotecan plus trastuzumab in metastatic breast cancer
2012-002347-23Phase 2Terminated
- Sponsor
- Danish Breast Cancer Cooperative Group
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and irinotecan in breast cancer, sponsored by Danish Breast Cancer Cooperative Group. Primary endpoint: Clinical benefit rate. Started Jun 2012; status: terminated.
02
Drugs
trastuzumabirinotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-002347-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002347-23.